Filgotinib for moderately to severely active ulcerative colitis

Expert Rev Gastroenterol Hepatol. 2022 Oct;16(10):927-940.doi: 10.1080/17474124.2022.2138857. Epub 2022 Nov 14.


Alessandro Mannucci 1 2Ferdinando D'Amico 1 2 3Ahmad El Saadi 2Laurent Peyrin-Biroulet 4 5Silvio Danese 1 2


Author information

1Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

2Vita-Salute San Raffaele University, Milan, Italy.

3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

4Department of Gastroenterology, University of Lorraine, CHRU-Nancy, F-54000, Nancy, France.

5Department of Gastroenterology, University of Lorraine, Inserm, NGERE, F-54000, Nancy, France.


Introduction: Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.

Areas covered: Pubmed, Scopus, and Embase databases were searched for all relevant studies reporting the efficacy and safety of filgotinib in patients with moderate to severe UC. We particularly focused on the risk of zoster infection and venous thromboembolism compared to other JAK inhibitors.

Expert opinion: Filgotinib has remarkable efficacy, safety, and tolerability profiles in the treatment of moderate-to-severe active UC. It can be used in both biologic-naïve and biologic-experienced patients. The rapid mechanism of action and its oral administration route make it a reliable therapeutic option.


© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.